Cargando…

2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)

BACKGROUND: HZ has high morbidity in immune-compromised hosts, including PLWH. Two vaccines against HZ are available, but their efficacy in PLWH is unknown. A surrogate marker of protection against HZ would facilitate efficacy studies of HZ vaccines in PLWH, as compared with HZ clinical outcome stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovar-Salazar, Adriana, McKhann, Ashley, Chen, Huichao, Bosch, Ronald, Weinberg, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253072/
http://dx.doi.org/10.1093/ofid/ofy210.1683
_version_ 1783373412510466048
author Tovar-Salazar, Adriana
McKhann, Ashley
Chen, Huichao
Bosch, Ronald
Weinberg, Adriana
author_facet Tovar-Salazar, Adriana
McKhann, Ashley
Chen, Huichao
Bosch, Ronald
Weinberg, Adriana
author_sort Tovar-Salazar, Adriana
collection PubMed
description BACKGROUND: HZ has high morbidity in immune-compromised hosts, including PLWH. Two vaccines against HZ are available, but their efficacy in PLWH is unknown. A surrogate marker of protection against HZ would facilitate efficacy studies of HZ vaccines in PLWH, as compared with HZ clinical outcome studies. To this goal, our study investigated the association of cytotoxic T lymphocytes (CTL) and regulatory T cells (Treg) with incident HZ in PLWH. METHODS: The study used peripheral blood mononuclear cells (PBMC) cryopreserved at mean (SD) of 2.7 (2.5) months before HZ from 31 PLWH cases on ART with plasma vRNA < 200 c/mL, and CD4 counts ≥200 cells/µL. 31 non-HZ controls were matched to cases by CD4 count, age, sex, race, parent study, and ART duration. T cell subsets were measured by flow cytometry after ex vivo VZV- and mock-restimulation and in freshly thawed unstimulated PBMC using the following markers: CD3, CD8, CD25, CD28, CD39, CD57, CD127, CTLA4, FOXP3, IFNg, IL10, KLRG1, LAG3, PD1, perforin, TGFb, TIM3 and TNFa. Data were analyzed by paired t-tests. RESULTS: At PBMC collection, PLWH had mean (SD) age 41 (10) years; 16 females; 28 White and 22 Black non-Hispanics; mean (SD) CD4 counts 501 (222) cells/µL; 56 (90%) vRNA < 50 c/mL; median ART duration 50 weeks. In unstimulated PBMC, HZ cases had higher %FOXP3+CD25+(CD4+) Treg compared with controls (P = 0.08). Cases generally had lower responses to ex vivo VZV-restimulation (after subtraction of mock) compared with controls, including %perforin+(CD8+) CTL (P = 0.07) and %IL10+(CD4+) (P = 0.04) and %TGFb+(CD4+) Treg (P = 0.07). %FOXP3+CD25+(CD4+) Treg in unstimulated PBMC did not correlate with VZV-specific %perforin+(CD8+) or %IFNg+(CD4+) effector T cells, but the VZV-specific effector T cell percentages correlated with each other (r = 0.24, P = 0.05). CONCLUSION: Although limited by small numbers, this study showed that before development of HZ, PLWH had marginally increased number of Treg in blood and decreased VZV-specific responses. VZV-specific Treg and CTL were equally lower in cases compared with controls, suggesting that a general low VZV-specific T cell responsiveness precedes HZ in PLWH. The lack of association between circulating Treg and VZV-specific T cell responses suggests independent mechanisms of action. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253072
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62530722018-11-28 2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH) Tovar-Salazar, Adriana McKhann, Ashley Chen, Huichao Bosch, Ronald Weinberg, Adriana Open Forum Infect Dis Abstracts BACKGROUND: HZ has high morbidity in immune-compromised hosts, including PLWH. Two vaccines against HZ are available, but their efficacy in PLWH is unknown. A surrogate marker of protection against HZ would facilitate efficacy studies of HZ vaccines in PLWH, as compared with HZ clinical outcome studies. To this goal, our study investigated the association of cytotoxic T lymphocytes (CTL) and regulatory T cells (Treg) with incident HZ in PLWH. METHODS: The study used peripheral blood mononuclear cells (PBMC) cryopreserved at mean (SD) of 2.7 (2.5) months before HZ from 31 PLWH cases on ART with plasma vRNA < 200 c/mL, and CD4 counts ≥200 cells/µL. 31 non-HZ controls were matched to cases by CD4 count, age, sex, race, parent study, and ART duration. T cell subsets were measured by flow cytometry after ex vivo VZV- and mock-restimulation and in freshly thawed unstimulated PBMC using the following markers: CD3, CD8, CD25, CD28, CD39, CD57, CD127, CTLA4, FOXP3, IFNg, IL10, KLRG1, LAG3, PD1, perforin, TGFb, TIM3 and TNFa. Data were analyzed by paired t-tests. RESULTS: At PBMC collection, PLWH had mean (SD) age 41 (10) years; 16 females; 28 White and 22 Black non-Hispanics; mean (SD) CD4 counts 501 (222) cells/µL; 56 (90%) vRNA < 50 c/mL; median ART duration 50 weeks. In unstimulated PBMC, HZ cases had higher %FOXP3+CD25+(CD4+) Treg compared with controls (P = 0.08). Cases generally had lower responses to ex vivo VZV-restimulation (after subtraction of mock) compared with controls, including %perforin+(CD8+) CTL (P = 0.07) and %IL10+(CD4+) (P = 0.04) and %TGFb+(CD4+) Treg (P = 0.07). %FOXP3+CD25+(CD4+) Treg in unstimulated PBMC did not correlate with VZV-specific %perforin+(CD8+) or %IFNg+(CD4+) effector T cells, but the VZV-specific effector T cell percentages correlated with each other (r = 0.24, P = 0.05). CONCLUSION: Although limited by small numbers, this study showed that before development of HZ, PLWH had marginally increased number of Treg in blood and decreased VZV-specific responses. VZV-specific Treg and CTL were equally lower in cases compared with controls, suggesting that a general low VZV-specific T cell responsiveness precedes HZ in PLWH. The lack of association between circulating Treg and VZV-specific T cell responses suggests independent mechanisms of action. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253072/ http://dx.doi.org/10.1093/ofid/ofy210.1683 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Tovar-Salazar, Adriana
McKhann, Ashley
Chen, Huichao
Bosch, Ronald
Weinberg, Adriana
2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
title 2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
title_full 2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
title_fullStr 2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
title_full_unstemmed 2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
title_short 2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH)
title_sort 2027. immune correlates of protection against herpes zoster (hz) in people living with hiv (plwh)
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253072/
http://dx.doi.org/10.1093/ofid/ofy210.1683
work_keys_str_mv AT tovarsalazaradriana 2027immunecorrelatesofprotectionagainstherpeszosterhzinpeoplelivingwithhivplwh
AT mckhannashley 2027immunecorrelatesofprotectionagainstherpeszosterhzinpeoplelivingwithhivplwh
AT chenhuichao 2027immunecorrelatesofprotectionagainstherpeszosterhzinpeoplelivingwithhivplwh
AT boschronald 2027immunecorrelatesofprotectionagainstherpeszosterhzinpeoplelivingwithhivplwh
AT weinbergadriana 2027immunecorrelatesofprotectionagainstherpeszosterhzinpeoplelivingwithhivplwh